Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01545141 · ClinicalTrials.gov registry record · Phase 1
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT01545141 is a Phase 1 study that was terminated before completion, run by Roswell Park Cancer Institute. The registered enrollment target is 15 participants.
The verdict
NCT01545141, a Phase 1 study, was terminated before completion, sponsored by Roswell Park Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
Determine the safety of a combination of IFN, celecoxib, and rintatolimod for patients with recurrent colorectal cancer. This will also test whether the above combination can help the immune system to fight the tumors. The results will allow the investigators to determine the "preferred" combination for subsequent extended studies.
Interventions
- DRUG Chemokin Modulatory Regimen (5 MU/m2)
- DRUG Chemokin Modulatory Regimen (10 MU/m2)
- DRUG Chemokin Modulatory Regimen (20 MU/m2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2012-10 |
| Est. Completion | 2017-04-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01545141
The ClinicalTrials.gov registry entry for NCT01545141 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Chemokin Modulatory Regimen (5 MU/m2) is the first listed.
NCT01545141 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01545141 about?
NCT01545141 is a clinical study titled "Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer". Determine the safety of a combination of IFN, celecoxib, and rintatolimod for patients with recurrent colorectal cancer. This will also test whether the above combination can help the immune system to fight the tumors. The results will allow the investigators to determine the "preferred" combination...
What is the current status of trial NCT01545141?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2012-10. Estimated completion is 2017-04-08.
What interventions are being tested in trial NCT01545141?
The interventions under investigation include: Chemokin Modulatory Regimen (5 MU/m2) (DRUG), Chemokin Modulatory Regimen (10 MU/m2) (DRUG), Chemokin Modulatory Regimen (20 MU/m2) (DRUG).
Who is sponsoring clinical trial NCT01545141?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.